Gene therapies for Parkinson's disease
Stephane’s team works on translational medicine projects, concerning neurodegenerative diseases, essentially Parkinson disease, Huntington disease, and Psychiatric disorders

Their major research programs relevant for Parkinson’s disease and related disorders as well as Psychiatric disorders are funded by national and/or European institutions as well as by private partnerships.

The aim of those projects are:

1- The neurological and neurosurgical assessment of biotherapies for neurodegenerative diseases at initial phase of clinical development following the demonstration of safety and efficacy in non-clinical experiments.

2- The development of neuromodulation approaches for drug-resistant psychiatric and neurological diseases using optogenetic technology to better understand brain circuitry abnormalities and define new therapeutic targets.

3- The development of new neurosurgical tools and devices to assess or administrate drugs, viral vectors, cells as well as electrical or light sources devices with the help of neuronavigation system and surgical robot.
Date: 13 March 2018, 16:00 (Tuesday, 9th week, Hilary 2018)
Venue: Sherrington Building, off Parks Road OX1 3PT
Venue Details: Sherrington Library
Speaker: Stephane Palfi (IMRB - Mondor Biomedical Research Institute)
Organising department: Department of Physiology, Anatomy and Genetics (DPAG)
Organiser: Melanie Witt (University of Oxford, Department of Earth Sciences, Department of Physiology Anatomy and Genetics)
Organiser contact email address: opdc.administrator@dpag.ox.ac.uk
Part of: OPDC Seminar Series (DPAG)
Topics:
Booking required?: Not required
Audience: Members of the University only
Editor: Melanie Witt